New 48-week data showed its dual-action drug outperformed placebo across key non-invasive liver tests.
Shares of Altimmune, Inc. (ALT) jumped 16% in premarket trading on Friday after it reported positive topline results from its Phase 2b IMPACT trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Pemvidutide is a drug that targets both GLP-1 and glucagon receptors and is used to treat liver diseases.
The company said that the 48-week data showed statistically significant improvements versus placebo in key non-invasive liver tests, including enhanced liver fibrosis and liver stiffness, with continued progress from week 24. The higher dose also delivered additional weight loss without signs of plateauing, while maintaining a favorable safety profile.
Altimmune also said it held a productive End-of-Phase 2 meeting with the FDA, aligning on plans for a registrational Phase 3 trial.
ALT was the top-trending tickers on Stocktwits at the time of writing.
Get updates to this developing story on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
